SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Capone Brian (Last) (First) (Middle) 150 CLOVE ROAD (Street) LITTLE FALLS NJ 07424 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CANTEL MEDICAL CORP [ CMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP and Princ. Accounting Ofr
	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2021
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $.10 per share	06/02/2021		D(1)(2)		12,216(1)(2)	D	$80.59(1)(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").

2. Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion.

	/s/ Brian Capone	06/02/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.